Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kinetics of mRNA Expression After GSK 692342 TB Vaccine
NCT01669096Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2012
- Primary completion
- Dec 2012
- Modality
- Split/Subunit Vaccines, Peptide-based Cancer Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of M72 + AS01E in Tuberculosis (TB), sponsored by GSK. Primary endpoints: Concentration of Specific Interferon Gamma (IFN-γ) Antibodies Secreted in Serum Samples at Day 47, Frequency of Mycobacterium Tuberculosis Fusion Protein (M72) Specific Cluster of Differentiation CD4+/CD8+ T Cells Expressing at Least Two Different Immune Markers at Day 60 and 7 more. Started Aug 2012; status: completed.
02
Drugs
M72 + AS01E
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT01669096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01669096.